Business Context and Reporting Period
Company: Eli Lilly & Co.
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2004
Business Overview: Eli Lilly is a global pharmaceutical company incorporated in Indiana. Its primary business segment is pharmaceutical products, with a non-material animal health segment. The company operates manufacturing and distribution facilities in the U.S., Puerto Rico, and 22 other countries, selling products in approximately 140 countries. Key therapeutic areas include neuroscience, endocrinology, oncology, and cardiovascular diseases.
Key Financial Metrics
Note: Specific revenue, profit, and cash flow figures for 2004 are incorporated by reference from the 2004 Annual Report (Exhibit 13) and are not explicitly stated in the provided text. The following metrics are available from the filing text:
- Research & Development Expenses: $2.69 billion for 2004 (up from $2.35 billion in 2003 and $2.15 billion in 2002).
- Employee Count: Approximately 44,500 total employees as of December 31, 2004, including 8,450 in R&D and 20,500 outside the U.S.
- Market Capitalization: Aggregate market value of common equity held by non-affiliates was approximately $68.5 billion as of the last business day of the second fiscal quarter.
- Outstanding Shares: 1,132,720,819 shares of common stock outstanding as of February 15, 2005.
- Share Repurchases: As of December 31, 2004, the company had purchased $2.08 billion of stock under a $3.0 billion program announced in March 2000. No shares were repurchased under this specific program during 2004; 59,000 shares were purchased in Q4 2004 related to employee stock option exercises.
- Legal Provisions: A provision of $36.0 million was recorded in Q4 2004 to resolve a marketing practices investigation regarding Evista.
Material Changes and Operational Updates
- R&D Strategy Shift: In 2004, the company terminated research in the inflammation area to reallocate resources, narrowing its pharmaceutical R&D focus from five to four therapeutic categories: central nervous system, endocrine diseases, cancer, and cardiovascular diseases.
- Product Approvals: Significant new approvals in 2004 included Cymbalta (depression and diabetic neuropathic pain), Alimta (mesothelioma and lung cancer), and Yentreve (stress urinary incontinence outside the U.S.).
- Wholesaler Restructuring: Beginning in 2005, the company restructured arrangements with U.S. wholesalers to reduce speculative buying and improve inventory data reliability.
- Patent Landscape: The filing details significant patent expirations and challenges, particularly for Zyprexa (compound patent expires 2011) and Evista, with ongoing litigation against generic manufacturers.
Guidance, Risks, and Contingencies
Legal Proceedings and Contingencies:
- Zyprexa Litigation: The company faces approximately 140 product liability cases (approx. 360 claimants) alleging Zyprexa caused diabetes or high blood-glucose levels. Additionally, there are tolling agreements with over 3,050 potential claimants. Generic patent challenges are pending in the U.S. and Germany.
- Marketing Investigations: The DOJ is investigating marketing practices for Evista (a $36 million provision recorded). The U.S. Attorney for the Eastern District of Pennsylvania is investigating marketing practices for Zyprexa, Prozac, and Prozac Weekly; the outcome is unpredictable and could involve criminal charges or civil penalties.
- Other Litigation: Pending suits involve DES (diethylstilbestrol) and thimerosal (vaccine preservative) claims, as well as Medicaid reimbursement pricing disputes in New York and Alabama.
Regulatory and Market Risks:
- Pricing Pressure: The company anticipates continued pricing pressures in the U.S. due to the Medicare Prescription Drug, Improvement and Modernization Act of 2003 (effective 2006) and state-level importation schemes.
- Intellectual Property: The company relies heavily on patents for market exclusivity. Generic competition upon patent expiration is expected to cause severe sales declines for affected products.
- Supply Chain: Reliance on single-source raw materials and third-party manufacturers (e.g., Takeda for Actos, Lonza/DSM for Xigris) poses supply interruption risks.
Outlook: Management expects a relatively neutral short-term impact from the 2006 Medicare legislation but notes long-term risks from pricing pressures. The company emphasizes continued investment in R&D to maintain competitiveness.
Investor Verification Checklist
- Financial Statements: Verify exact 2004 Net Sales, Net Income, and Operating Cash Flow figures in the 2004 Annual Report (Exhibit 13), as they are not explicitly listed in the 10-K text provided.
- Zyprexa Exposure: Monitor the status of the consolidated product liability litigation and the outcome of the generic patent challenges, as an adverse outcome could materially impact liquidity and operations.
- Regulatory Settlements: Track the resolution of the DOJ and U.S. Attorney investigations into marketing practices to assess potential additional fines or penalties beyond the $36 million provision.
- Patent Expirations: Review the timeline for key patent expirations (Zyprexa 2011, Humalog 2013, ReoPro 2015) and the status of patent term extension applications for Alimta and Cymbalta.
- R&D Pipeline: Assess the progress of new drug candidates in the four focused therapeutic areas following the divestment of inflammation research.